Prima BioMed Makes Progress For Breast Cancer Research
Edison | Jul 27, 2016 09:43AM ET
Prima Biomed Ltd (NASDAQ:PBMD, AX:PRR) has progressed to the final stage of dose selection for its Phase IIb trial of IMP321 in breast cancer, and is on track to commence randomisation in Q416. IMP321 is a soluble LAG-3 fusion protein that doubled tumour response rates in Phase IIa.
Separately, partner Novartis has expanded its Phase I LAG-3 programme in solid tumours and GSK plans to move its partnered programme in autoimmune disease into Phase II this year. With the company’s development of in-house and partnered LAG-3 programmes on track, our valuation increases slightly to A$282m (14c/share).
First cohort in AIPAC safely treated
The first six patients have safely completed treatment in the AIPAC Phase IIb trial of IMP321 in breast cancer. No drug-related serious adverse events were observed and data demonstrated activation of blood monocytes/dendritic cells and CD8 T-cells.
Recruitment is underway in the second cohort of nine patients who will receive 30mg of IMP321 in combination with paclitaxel, compared to 6mg in the first cohort. Results for both cohorts are expected in Q416; the trial will then move to the randomisation phase in 196 patients.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.